Fierce Biotech April 17, 2024
Sanofi’s global collaboration with IGM Biosciences has shrunk by half. The companies will now focus only on developing three IgM agonist antibodies for immunology and inflammation and shed three related oncology targets.
The move follows news of two other oncology pullbacks by the pharma earlier this month.
The exclusive agreement, initially inked in 2022, saw Sanofi pay $150 million upfront and offer potential milestones exceeding $6 billion. In return, the French drugmaker received a stake in six IGM antibodies, which have ten binding units compared to the industry standard of two. IGM believes the additional units will allow its antibodies to bind to more targets with more power.
Now, Sanofi has slimmed down the agreement, handing back global rights to...
Today's Sponsors
Today's Sponsor